No Prescription |
 |
 | ||
|
URISPAS Generic Flavoxate |
|
| ||
No Prescription » Prescription Drugs 16 » URISPAS Generic Flavoxate Flavoxate is used to relieve painful frequent or nighttime urination and urgency that may occur with infections of the prostate bladder or kidneys. The drug works by relaxing the muscles involved with urination. However flavoxate is not an antibiotic; it does not cure infections.Flavoxate comes as a tablet. Flavoxate usually is taken three or four times a day. This drug may be taken with or without food. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take flavoxate exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy URISPAS Generic Flavoxate and other Prescription Drugs 16 products online at Medstore. 975
About URISPAS Generic Flavoxate: Product Type: Prescription Drugs 16 URISPAS ( Generic Flavoxate ) URISPAS (Generic Flavoxate) Generic Flavoxate 200 mg Tab 24 (3 x 8) Generic Flavoxate URISPAS
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
